Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | L3MBTL3 | Q96JM7 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.38 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.35 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 2/20 | 0.33 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2904654 | 1.00 | HTR6 (0.56) | HTR6HPGDKMT2ASMN1; SMN2L3MBTL3 | |
| Hydrochloric Acid SCHEMBL2973444 | 0.98 | HTR6 (0.54) | HTR6HPGDKMT2ASMN1; SMN2L3MBTL3 | |
| SCHEMBL12469538 | 0.93 | HTR6 (0.54) | HTR6HPGDKMT2ASMN1; SMN2L3MBTL3 | |
| SCHEMBL524430 | 0.93 | HTR6 (0.59) | HTR6HPGDKMT2ASMN1; SMN2L3MBTL3 | |
| SCHEMBL1507120 | 0.93 | HTR6 (0.65) | HTR6HPGDKMT2ASMN1; SMN2L3MBTL3 | |
| SCHEMBL6134512 | 0.91 | HTR6 (0.63) | HTR6HPGDKMT2ASMN1; SMN2L3MBTL3 | |
| SCHEMBL9902700 | 0.91 | HTR6 (0.63) | HTR6HPGDKMT2ASMN1; SMN2L3MBTL3 | |
| Hydrochloric Acid SCHEMBL4321509 | 0.91 | HTR6 (0.57) | HTR6HPGDKMT2ASMN1; SMN2L3MBTL3 | |
| Hydrochloric Acid SCHEMBL450486 | 0.91 | HTR6 (0.57) | HTR6HPGDKMT2ASMN1; SMN2L3MBTL3 | |
| SCHEMBL894571 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1591443-B1 | PYRAZOLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2010-08-25 | — | — | EP | claimed |
| US-7622471-B2 | Pyrazole derivatives having a pyridazine and pyridine functionality | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-11-24 | — | — | US | claimed |
| US-20060189591-A1 | Five-membered heterocyclic derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-08-24 | — | — | US | claimed |
| US-20060128685-A1 | Pyrazole derivative | DAIICHI PHARMACEUTICAL CO., LTD., (JP) | 2006-06-15 | — | — | US | claimed |
| EP-1621537-A1 | FIVE-MEMBERED HETEROCYCLIC DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-02-01 | — | — | EP | claimed |
| EP-1591443-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-02 | — | — | EP | claimed |
| EP-4626871-A1 | CD93 INHIBITORS | Universität Bern (CH) | 2025-10-08 | — | — | EP | disclosed |
| WO-2024115637-A1 | CD93 INHIBITORS | Universität Bern (CH) | 2024-06-06 | — | — | WO | disclosed |
| EP-4378932-A1 | NOVEL CD93 INHIBITORS | Universität Bern (CH) | 2024-06-05 | — | — | EP | disclosed |
| CN-114025847-B | Compounds and compositions as modulators of TLR signaling | 神经孔疗法股份有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20220298155-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | NEUROPORE THERAPIES, INC. (US) | 2022-09-22 | — | — | US | disclosed |
| WO-2022140325-A1 | 6-SUBSTITUTED INDOLE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| US-11299487-B2 | Compounds and compositions as modulators of TLR signaling | NEUROPORE THERAPIES, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| US-20060189591-A1 | Five-membered heterocyclic derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| US-20060128685-A1 | Pyrazole derivative | DAIICHI PHARMACEUTICAL CO., LTD., (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1621537-A1 | FIVE-MEMBERED HETEROCYCLIC DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-02-01 | — | — | EP | disclosed |
| EP-1591443-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-02 | — | — | EP | disclosed |
| US-4311616-A | Method of preparing perfume compositions that contain tricyclo[5.2.1.02 ]decane carboxylic acid esters | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (HENKEL KGAA) HENKELSTRASSE 67, A CORP. OF GERMANY (DE) | 1982-01-19 | — | — | US | disclosed |
| US-4191760-A | ANTISCHIZOPHRENICS | ABBOTT LABORATORIES (US) | 1980-03-04 | — | — | US | disclosed |
| US-4096261-A | ANTISCHIZOPHRENICS | ABBOTT LABORATORIES (US) | 1978-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128685-A1 | Pyrazole derivative | PTGS1, PTGS2, PTGER1 | HTR6 1281/4885HPGD 18/4885KMT2A 4370/4885 |
| US-20220298155-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | TLR3, TLR6, TLR4 | HTR6 911/4885HPGD 2872/4885KMT2A 4366/4885 |
| US-20060189591-A1 | Five-membered heterocyclic derivative | PTGS1, PTGIS, PTGS2 | HTR6 1890/4885HPGD 19/4885KMT2A 4143/4885 |
| US-11299487-B2 | Compounds and compositions as modulators of TLR signaling | TLR3, TLR6, TLR4 | HTR6 529/4885HPGD 2978/4885KMT2A 3864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.